Fortress Biotech, Inc. FBIOP
15.66 USD +0.21 (+1.36%)
At closeNov 10, 2026, 6:46 PM EST
15.55 -0.11 -0.70%
After hours · Nov 10, 6:46 PM ET
15.20 Day range 15.67
6.27 52-week range 21.43
- YTD
- +65.02%
- 1 year
- +135.49%
News
globenewswire.com Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
globenewswire.com Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130…
seekingalpha.com Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends? Fortress Biotech now holds $256 million in cash and only $39 million in debt, establishing a fortress balance sheet. FBIO's recent windfall from the Menkes disease drug sale positions it to easily…
globenewswire.com Fortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference MIAMI, May 18, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
globenewswire.com Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205…
globenewswire.com Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
globenewswire.com Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights ZYCUBO® approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205…
defenseworld.net Fortress Biotech (NASDAQ:FBIOP) Stock Price Up 22.9% – Here’s What Happened Fortress Biotech, Inc. (NASDAQ: FBIOP - Get Free Report)'s share price rose 22.9% during mid-day trading on Monday. The stock traded as high as $13.79 and last traded at $13.52. Approximately 205,100…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
globenewswire.com UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium…
globenewswire.com Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that Cyprium…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session 
globenewswire.com Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium
globenewswire.com Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress…
seekingalpha.com Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript Fortress Biotech, Inc. ( FBIO ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jaclyn Jaffe - Senior Director of Corporate Operations Claude Maraoui - Founder, President,…
defenseworld.net Fortress Biotech (NASDAQ:FBIOP) Stock Price Down 1.9% – Time to Sell? Fortress Biotech, Inc. (NASDAQ: FBIOP - Get Free Report)'s share price was down 1.9% during mid-day trading on Monday. The stock traded as low as $6.80 and last traded at $6.87. Approximately 7,918…
globenewswire.com Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session 
globenewswire.com Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy
globenewswire.com Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S.…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session 
globenewswire.com Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term…
globenewswire.com Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value…
globenewswire.com Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics Fortress will receive ~$28 million shortly after closing and is eligible for an additional contingent value right (CVR) of up to $4.8 million, plus a 2.5% royalty on future net sales of UNLOXCYT™…
benzinga.com Stocks Which Set New 52-Week Low Yesterday, October 22nd 
benzinga.com Stocks Which Set New 52-Week Low Yesterday, August 2nd